We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GeneNews Granted U.S. Patent for Chagas Disease Based on Sentinel Principle™ Platform
News

GeneNews Granted U.S. Patent for Chagas Disease Based on Sentinel Principle™ Platform

GeneNews Granted U.S. Patent for Chagas Disease Based on Sentinel Principle™ Platform
News

GeneNews Granted U.S. Patent for Chagas Disease Based on Sentinel Principle™ Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GeneNews Granted U.S. Patent for Chagas Disease Based on Sentinel Principle™ Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GeneNews Limited has announced it has been granted U.S. Patent No. 7,473,528 entitled "Method for the detection of Chagas disease related gene transcripts in blood".

This patent protects the Company's discovery of a blood biomarker-based method of testing for Chagas disease, a serious and potentially fatal disease resulting from parasitic infection. Chagas disease is a significant public health issue affecting more than 11 million people worldwide each year.

"The Sentinel Principle™ technology is the basis of not only this issued patent but also for the personalized health management system we are developing which applies genomic information to monitor and address health concerns on an individualized basis," stated Dr. Choong-Chin Liew, the discoverer of the Sentinel Principle and Co-founder, Chief Scientist and Director of GeneNews.

"GeneNews has a broad array of pending patent applications in diverse disease areas including oncology, cardiovascular, neurological and inflammatory conditions," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews.

"This is our first patent issuance based on our Sentinel Principle platform technology and represents an important initial milestone to realize commercial value from our pipeline of discoveries." The Company currently has five issued patents and more than 70 pending patent applications, the majority of which are based on the application of the Sentinel Principle.
Advertisement